双时相FDG PET/CT预测乳腺癌生物学特征
该回顾性研究纳入1523例乳腺癌患者,于治疗前FDG给药后1小时和2小时行PET/CT,计算原发肿瘤SUVmax1、SUVmax2及滞留指数(RI)。结果显示代谢参数与肿瘤大小、淋巴结转移、组织学、核分级、脉管侵犯及分子亚型均相关(均P<0.001);在FDG摄取显著的肿瘤中,RI与恶性特征相关,双时相显像有助于区分Luminal A型与其他亚型。
要点
- 双时相FDG PET/CT的滞留指数(RI)与乳腺癌多项恶性特征相关。
- 在FDG摄取显著的肿瘤中,RI可辅助区分Luminal A型与Luminal B型、HER2阳性及三阴性乳腺癌。
- 各分子亚型中位RI分别为Luminal A型0%、Luminal B型5.3%、HER2阳性6.9%、三阴性11.4%。
核心结论
- 在FDG摄取显著的乳腺癌中,延迟相FDG PET/CT计算的滞留指数(RI)与恶性特征相关。
- 双时相显像有助于区分Luminal A型与Luminal B型、HER2阳性及三阴性乳腺癌。
研究设计与样本
- 回顾性研究,共纳入1523例乳腺癌患者。
- 治疗前于FDG给药后1小时和2小时行PET/CT,计算原发肿瘤SUVmax1、SUVmax2及RI,并评估肿瘤组织学、核分级、脉管侵犯和分子亚型等生物学特征。
主要发现
- 1523例中Luminal A型463例(30.4%)、Luminal B型661例(43.4%)、HER2阳性229例(15.0%)、三阴性157例(10.3%)。
- SUVmax1、SUVmax2和RI的中位值分别为2.2、2.3和2.6%。
- 代谢参数与肿瘤大小、淋巴结转移、组织学、核分级、脉管侵犯及分子亚型均相关(均P<0.001)。
- 各分子亚型中位RI:Luminal A型0%、Luminal B型5.3%、HER2阳性6.9%、三阴性11.4%。
- T2至T4期肿瘤亚组分析中,RI与淋巴结转移、组织学、核分级及分子亚型相关(Luminal A型4.8%、Luminal B型12.3%、HER2阳性15.8%、三阴性16.3%)。
关键数值与推荐
- RI由双时相FDG PET/CT(1小时和2小时)计算,原文未报告具体计算公式。
- 在FDG摄取显著的肿瘤中,RI与恶性特征相关;双时相显像有助于区分Luminal A型与Luminal B型、HER2阳性及三阴性乳腺癌。
临床怎么用
- 对FDG摄取显著的乳腺癌患者,可考虑双时相FDG PET/CT计算RI,辅助无创评估肿瘤生物学特征及分子亚型倾向。
- RI有助于提示Luminal A型与侵袭性较强亚型(Luminal B型、HER2阳性、三阴性)的鉴别,为后续诊疗决策提供参考。
局限性
- 本研究为回顾性设计。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to assess whether the retention index (RI) determined using dual-phase 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) reflects the malignant features of breast cancer. METHODS: A total of 1,523 patients with breast cancer were retrospectively evaluated. PET/CT scans were performed at 1 h and 2 h after FDG administration before treatment. The maximum standardized uptake value (SUVmax) at both time points (SUVmax1 and SUVmax2) in the primary tumour and RI were calculated. Primary tumour tissues were evaluated in terms of biological features, such as histology, nuclear grade, lymphovascular invasion and molecular subtype. RESULTS: Of the 1,523 patients, 463 (30.4%) had luminal A-like, 661 (43.4%) had luminal B-like, 229 (15.0%) had human epidermal growth factor receptor 2-positive (HER2-positive), and 157 (10.3%) triple-negative breast cancer. The median SUVmax1, SUVmax2 and RI values were 2.2, 2.3 and 2.6%, respectively. These metabolic parameters were correlated with tumour size, nodal metastasis, histology, nuclear grade, lymphovascular invasion, and molecular subtype (all P < 0.001). The median RI values were 0% in luminal A-like, 5.3% in luminal B-like, 6.9% in HER2-positive, and 11.4% in triple-negative breast cancer. RI was associated with malignant features when the tumour accumulated a significant amount of FDG. In a subanalysis of patients with tumours of stages T2 to T4, RI was correlated with nodal metastasis, histology, nuclear grade, and molecular subtype (luminal A-like 4.8%, luminal B-like 12.3%, HER2-positive 15.8%, and triple-negative 16.3%). CONCLUSION: RI determined using delayed-phase FDG PET/CT is associated with malignant features in breast cancers with significant FDG uptake. Dual-phase imaging was helpful in distinguishing luminal A-like breast cancer from luminal B-like, HER2-positive, and triple-negative breast cancers.
引用
- Sasada S, Masumoto N, Suzuki E, et al. Prediction of biological characteristics of breast cancer using dual-phase FDG PET/CT. Eur J Nucl Med Mol Imaging. 2019. PMID: 30648199. doi:10.1007/s00259-019-4259-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。